Nordson Corp
NDSN: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$377.00 | Vyjys | Jyzwglfrb |
Nordson: Maintaining $233 Fair Value Estimate After Atrion Acquisition Announcement
We are maintaining our $233 fair value estimate for narrow-moat Nordson after the company announced an agreement to acquire Atrion, a publicly traded provider of medical infusion and cardiovascular solutions, for roughly $800 million. In 2023 Atrion generated $169 million in revenue and $39 million in EBITDA. Nordson expects the deal to close by the end of fiscal 2024.